NASDAQ:VIVO - Meridian Bioscience Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$17.10 +0.51 (+3.07 %)
(As of 03/20/2019 03:03 PM ET)
Previous Close$16.59
Today's Range$16.60 - $17.12
52-Week Range$13.75 - $19.84
Volume13,786 shs
Average Volume229,925 shs
Market Capitalization$726.58 million
P/E Ratio23.05
Dividend Yield3.06%
Beta0.49
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the Alethia brand; rapid immunoassays, a single-use immunoassays under the ImmunoCard and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the PREMIER brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand. This segment's products are primarily used in the detection of infectious diseases caused by various bacteria, viruses, parasites, and pathogens. Its products consists of gastrointestinal assays, including tests for C. difficile, Enterohemorrhagic E. coli, Campylobacter jejuni, H. pylori, Cryptosporidium, giardia lamblia, and calprotectin; respiratory illness assays, such as tests for Group A Streptococcus, Influenza, M. pneumoniae, Bordetella pertussis, and respiratory syncytial virus; blood chemistry assays; and tests for Group B Streptococcus, Chlamydia trachomatis, Neisseria gonorrhea, Herpes Simplex Virus Type 1 and Type 2, and Malaria. This segment sells its products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. Meridian Bioscience, Inc. was founded in 1976 and is headquartered in Cincinnati, Ohio.

Receive VIVO News and Ratings via Email

Sign-up to receive the latest news and ratings for VIVO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:VIVO
CUSIP58958410
Phone513-271-3700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$213.57 million
Cash Flow$0.9959 per share
Book Value$4.14 per share

Profitability

Net Income$23.84 million

Miscellaneous

Employees585
Market Cap$726.58 million
Next Earnings Date4/25/2019 (Estimated)
OptionableOptionable

Meridian Bioscience (NASDAQ:VIVO) Frequently Asked Questions

What is Meridian Bioscience's stock symbol?

Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO."

How often does Meridian Bioscience pay dividends? What is the dividend yield for Meridian Bioscience?

Meridian Bioscience declared a quarterly dividend on Friday, January 25th. Investors of record on Monday, February 4th will be paid a dividend of $0.125 per share on Thursday, February 14th. This represents a $0.50 dividend on an annualized basis and a dividend yield of 2.92%. The ex-dividend date of this dividend is Friday, February 1st. View Meridian Bioscience's Dividend History.

How were Meridian Bioscience's earnings last quarter?

Meridian Bioscience, Inc. (NASDAQ:VIVO) posted its earnings results on Thursday, January, 24th. The company reported $0.20 EPS for the quarter, beating the Zacks' consensus estimate of $0.18 by $0.02. The company had revenue of $51.48 million for the quarter, compared to analysts' expectations of $51.50 million. Meridian Bioscience had a net margin of 12.06% and a return on equity of 19.17%. The firm's quarterly revenue was down 1.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.15 EPS. View Meridian Bioscience's Earnings History.

When is Meridian Bioscience's next earnings date?

Meridian Bioscience is scheduled to release their next quarterly earnings announcement on Thursday, April 25th 2019. View Earnings Estimates for Meridian Bioscience.

What guidance has Meridian Bioscience issued on next quarter's earnings?

Meridian Bioscience updated its FY19 earnings guidance on Thursday, January, 24th. The company provided earnings per share guidance of $0.74-0.76 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.76. The company issued revenue guidance of $214-218 million (Flat to +2%), compared to the consensus revenue estimate of $221.13 million.Meridian Bioscience also updated its FY 2019 guidance to $0.74-0.76 EPS.

Has Meridian Bioscience been receiving favorable news coverage?

News headlines about VIVO stock have trended somewhat positive on Wednesday, InfoTrie reports. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Meridian Bioscience earned a media sentiment score of 0.7 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 7.0 out of 10, meaning that recent news coverage is likely to have an impact on the company's share price in the near term.

Who are some of Meridian Bioscience's key competitors?

What other stocks do shareholders of Meridian Bioscience own?

Who are Meridian Bioscience's key executives?

Meridian Bioscience's management team includes the folowing people:
  • Mr. John P. Kenny, CEO, Exec. VP of Diagnostics Bus. Unit & Director (Age 50)
  • Mr. Lawrence J. Baldini, Exec. VP of Global Operations (Age 60)
  • Ms. Susan D. Rolih, Consultant (Age 70)
  • Ms. Melissa A. Lueke, Consultant (Age 56)
  • Mr. Eric S. Rasmussen, Exec. VP & CFO (Age 51)

Who are Meridian Bioscience's major shareholders?

Meridian Bioscience's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.85%), Dimensional Fund Advisors LP (4.48%), Dimensional Fund Advisors LP (4.48%), Norges Bank (2.99%), Geode Capital Management LLC (1.93%) and Geode Capital Management LLC (1.93%). Company insiders that own Meridian Bioscience stock include Dwight E Ellingwood, John A Kraeutler, John Mccune Jr Rice, John Mcilwraith and Lawrence Baldini. View Institutional Ownership Trends for Meridian Bioscience.

Which institutional investors are selling Meridian Bioscience stock?

VIVO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Assenagon Asset Management S.A., New York State Common Retirement Fund, Bank of New York Mellon Corp, GSA Capital Partners LLP, Connor Clark & Lunn Investment Management Ltd., Prudential Financial Inc. and Segall Bryant & Hamill LLC. View Insider Buying and Selling for Meridian Bioscience.

Which institutional investors are buying Meridian Bioscience stock?

VIVO stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Vaughan Nelson Investment Management L.P., WINTON GROUP Ltd, Los Angeles Capital Management & Equity Research Inc., Municipal Employees Retirement System of Michigan, Two Sigma Investments LP, BlackRock Inc. and Acadian Asset Management LLC. Company insiders that have bought Meridian Bioscience stock in the last two years include Dwight E Ellingwood, John A Kraeutler, John Mccune Jr Rice and John Mcilwraith. View Insider Buying and Selling for Meridian Bioscience.

How do I buy shares of Meridian Bioscience?

Shares of VIVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Meridian Bioscience's stock price today?

One share of VIVO stock can currently be purchased for approximately $17.10.

How big of a company is Meridian Bioscience?

Meridian Bioscience has a market capitalization of $726.58 million and generates $213.57 million in revenue each year. The company earns $23.84 million in net income (profit) each year or $0.74 on an earnings per share basis. Meridian Bioscience employs 585 workers across the globe.

What is Meridian Bioscience's official website?

The official website for Meridian Bioscience is http://www.meridianbioscience.com.

How can I contact Meridian Bioscience?

Meridian Bioscience's mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The company can be reached via phone at 513-271-3700.


MarketBeat Community Rating for Meridian Bioscience (NASDAQ VIVO)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  222 (Vote Outperform)
Underperform Votes:  350 (Vote Underperform)
Total Votes:  572
MarketBeat's community ratings are surveys of what our community members think about Meridian Bioscience and other stocks. Vote "Outperform" if you believe VIVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VIVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel